This company listing is no longer active
Neuropathix Management
Management criteria checks 2/4
Neuropathix's CEO is Dean Petkanas, appointed in Jul 2018, has a tenure of 5.25 years. directly owns 17.03% of the company’s shares, worth $4.99K. The average tenure of the management team and the board of directors is 5.3 years and 5.3 years respectively.
Key information
Dean Petkanas
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.3yrs |
| CEO ownership | 17.0% |
| Management average tenure | 5.3yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$529k | US$240k | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$4m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$420k | US$240k | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$260k | US$240k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | US$242k |
| Dec 31 2018 | US$240k | US$240k | US$937k |
| Sep 30 2018 | n/a | n/a | US$1m |
| Dec 31 2017 | US$300k | US$300k | -US$2m |
| Dec 31 2016 | US$273k | US$273k | -US$1m |
Compensation vs Market: Insufficient data to establish whether Dean's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Dean's compensation with company performance.
CEO
Dean Petkanas (57 yo)
5.3yrs
Tenure
US$529,130
Compensation
Mr. Petkanas serves as Chairman and Chief Executive Officer of KannaLife Sciences, Inc. Mr. Petkanas has been a Managing Member of Excelsior Wealth Group, LLC since October 2003. Mr. Petkanas served as a S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.3yrs | US$529.13k | 17.03% $ 5.0k | |
| Founder | 5.3yrs | US$224.52k | 5.58% $ 1.6k | |
| Chief Financial Officer | 5.3yrs | US$139.76k | 1.58% $ 464.1 | |
| Chief Scientific Officer | 5.3yrs | US$119.73k | 1.56% $ 458.1 | |
| Chief Pharmacologist | no data | no data | no data | |
| Chief Chemist | no data | no data | no data |
5.3yrs
Average Tenure
61yo
Average Age
Experienced Management: NPTX's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.3yrs | US$529.13k | 17.03% $ 5.0k | |
| Founder | 5.3yrs | US$224.52k | 5.58% $ 1.6k | |
| Independent Director | 5.3yrs | US$59.82k | 0.26% $ 75.0 | |
| Non-Employee Director | 6.3yrs | US$59.82k | 0.26% $ 75.0 | |
| Member of Board of Advisors | 3.3yrs | no data | no data | |
| Chairman of the Scientific Advisory Board | 3.1yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$88.72k | 0.26% $ 75.0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
5.3yrs
Average Tenure
57yo
Average Age
Experienced Board: NPTX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/22 15:42 |
| End of Day Share Price | 2023/10/19 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuropathix, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|